Roivant Development Code News Today

TOKYO, Jan 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of

TOKYO, Jan 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV). H3B-8800 (Roivant's Development Code: RVT-2001) is a splicing modulator compound, discovered by Eisai's...